This episode is a rebroadcast of the ACCP Cardiology PRN webinar where Drs. Kristen De Almeida and Augustus (Rob) Hough reviewed the DANGER-SHOCK and ULTIMATE-DAPT trials released at the ACC 24 meeting.
The views expressed in this presentation reflect those of the presenter, and not necessarily those of the Department of Veterans Affairs or Public Health Service.
0:00-1:32: Introduction
1:33-7:14: The DANGER-SHOCK Trial
7:15-12:21: The ULTIMATE-DAPT Trial
12:22-16:27: Questions
16:28-16:59: Closing
References:
DANGER-SHOCK
Møller JE, Engstrøm T, Jensen LO, et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024;390(15):1382-1393. doi:10.1056/NEJMoa2312572
ULTIMATE-DAPT
Ge Z, Kan J, Gao X, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial [published correction appears in Lancet. 2024 May 11;403(10439):1854. doi: 10.1016/S0140-6736(24)00929-2]. Lancet. 2024;403(10439):1866-1878. doi:10.1016/S0140-6736(24)00473-2
CardioScripts 